Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adapalene/benzoyl peroxide/clindamycin phosphate - Bausch Health Companies

Next Previous
Drug Profile

Adapalene/benzoyl peroxide/clindamycin phosphate - Bausch Health Companies

Alternative Names: Benzoyl peroxide/clindamycin phosphate/adapalene; Cabtreo; Clindamycin phosphate/adapalene/benzoyl peroxide; IDP 126

Latest Information Update: 17 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Valeant Pharmaceuticals International
  • Developer Bausch Health Companies
  • Class Adamantanes; Anti-inflammatories; Antiacnes; Antibacterials; Benzoic acids; Keratolytics; Lincosamides; Naphthalenes; Oxidants; Pyrrolidines; Retinoids; Small molecules
  • Mechanism of Action Keratinocyte inhibitors; Protein 50S ribosomal subunit inhibitors; Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 11 Sep 2024 Registered for Acne vulgaris (In adolescents, In adults) in Canada (Topical)
  • 27 Feb 2024 Launched for Acne vulgaris in USA (Topical) in the first quarter of 2024
  • 20 Oct 2023 Bausch Health Companies announces intention to launch Adapalene/benzoyl peroxide/clindamycin phosphate (In adolescents, In adults) in USA (Topical, Gel) in Acne vulgaris in Q1 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top